However, antibodies to the programmed death protein 1 (PD-1), such as the monotherapy drug pembrolizumab, can be utilized as a first-line treatment for the metastatic NSCLC patients, without sensitizing the anaplastic lymphoma kinase (ALK) or epidermal growth factor receptor (EGFR) changes with the programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or higher (9). The gene discussed is ALK; the disease is neoplasm.